MHRA to review the safety and use of LABAs

The MHRA is to review the use of the long-acting beta-2 agonists (LABAs) formoterol and salmeterol in the treatment of asthma and COPD patients.

The drugs play a part in long-term control of chronic asthma when used as add-on therapy to treatment with corticosteroids.

They are used in COPD treatment if the symptoms have not been controlled by short-acting bronchodilators.

The review will address the safety and appropriate use of LABAs in asthma and COPD.

Understanding how corticosteroid inhalers can influence the effects of formoterol and salmeterol in the case of asthma, and how the clinical effects of salmeterol and formoterol change with different doses are areas to be addressed by the review.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in